Regulatory Rapporteur March 2026 – Contents
The innovation era: Where biology meets technology
Navigating regulatory pathways for live biotherapeutics in the US and EU: Challenges and opportunities
Cell therapy, gene therapy and tissue-engineered product manufacturing: Technical challenges, enablers and regulatory evolution
Navigating Advanced Therapy Medicinal Product regulatory changes: European Medicines Agency and UK guidance updates
Beyond product approval: Bridging the gap between regulatory success and patient access for biosimilars
The EU’s Health Technology Assessment Regulation: Implementation one year on
WMA declarations: Helsinki in the spotlight and Taipei in the background
TOPRA Annual Lecture 2026: The Global Imperative for Responsible AI in Healthcare
- Previous
- Next
FDA launches framework for accelerating development of individualised therapies for ultra-rare diseases
This industry news explores new FDA draft guidance that considers the use of the plausible mechanism framework to develop individualised medicines where randomised controlled trials are not feasible.
MHRA seeks views on indefinite acceptance of CE-marked medical devices
This industry news update summarises the MHRA proposals for indefinite recognition of CE-marked medical devices in Great Britain and the potential impact for health systems and patients.
New ICH M15 Guideline sets harmonised framework for MIDD
This industry news update gives details of the ICH M15 adoption and its aim to establish standardised good practice for the use of evidence derived from model-informed drug development.
More news
FDA approves non-invasive device for pancreatic cancer treatment
This industry news update shares details of the FDA’s approval of Optune Pax, a medical device enabling treatment in a home setting.
DIN SPEC 91509: A milestone for structured, digital medical device documentation
This industry news update introduces a new model that will help with the digitalisation of documentation under EU law.
MHRA points to clinical trial growth and faster assessment routes
This industry news update shares how clinical trials have grown over the past year and new regulations coming into effect.
MHRA invites Call for Evidence to assess AI regulation
This industry news update explains the reason for the MHRA’s Call for Evidence for AI regulation and provides guidance.
RegRapPod − InConversation with Parexel
InConversation talks Joint Clinical Assessment with Sangeeta Budhia and Sinan Sarac
RegRapPod − InConversation with Zohra Nasir and Aksa Rahman
InConversation talks careers with Zohra Nasir and Aksa Rahman
- Previous
- Next
The Organisation for Professionals in Regulatory Affairs
- Contact us
- Copyright © 2015-2026 The Organisation for Professionals in Regulatory Affairs Ltd. t/a Regulatory Rapporteur - All rights reserved